In IPWatchdog, we argued that by taking Hikma v. Amarin, the Supreme Court chose a narrow drug-pricing fight over the patent questions that matter.

In Truth on the Market, we argued that Hikma v. Amarin reflects a fatal conceit: that courts and regulators can engineer cheaper drugs.

In Truth on the Market, we argued that trade enforcement, not imported foreign price controls, is the right answer to high U.S. drug prices.

In comments to CMS, we opposed the GLOBE and GUARD models, which would tie Medicare drug payments to foreign government-set prices.